Related Experiment Video
Updated: Jan 25, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
Intracellular Delivery of an Antibody Targeting Gasdermin-B Reduces HER2 Breast Cancer Aggressiveness
Ángela Molina-Crespo1,2, Ana Cadete3,4, David Sarrio1,2
1Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), IdiPaz, Madrid, Spain.
Purpose:
Gasdermin B (GSDMB) overexpression/amplification occurs in about 60% of HER2 breast cancers, where it promotes cell migration, resistance to anti-HER2 therapies, and poor clinical outcome. Thus, we tackle GSDMB cytoplasmic overexpression as a new therapeutic target in HER2 breast cancers.
Experimental Design:
We have developed a new targeted nanomedicine based on hyaluronic acid-biocompatible nanocapsules, which allow the intracellular delivery of a specific anti-GSDMB antibody into HER2 breast cancer cells both in vitro and in vivo.
Results:
Using different models of HER2 breast cancer cells, we show that anti-GSDMB antibody loaded to nanocapsules has significant and specific effects on GSDMB-overexpressing cancer cells' behavior in ways such as (i) lowering the in vitro cell migration induced by GSDMB; (ii) enhancing the sensitivity to trastuzumab; (iii) reducing tumor growth by increasing apoptotic rate in orthotopic breast cancer xenografts; and (iv) diminishing lung metastasis in MDA-MB-231-HER2 cells in vivo. Moreover, at a mechanistic level, we have shown that AbGB increases GSDMB binding to sulfatides and consequently decreases migratory cell behavior and may upregulate the potential intrinsic procell death activity of GSDMB.
Conclusions:
Our findings portray the first evidence of the effectiveness and specificity of an antibody-based nanomedicine that targets an intracellular oncoprotein. We have proved that intracellular-delivered anti-GSDMB reduces diverse protumor GSDMB functions (migration, metastasis, and resistance to therapy) in an efficient and specific way, thus providing a new targeted therapeutic strategy in aggressive HER2 cancers with poor prognosis.
Insights
Targeting Gasdermin B (GSDMB) with nanomedicine offers a new strategy for HER2 breast cancers. This approach reduces tumor growth, metastasis, and therapy resistance by delivering an anti-GSDMB antibody intracellularly.
Area of Science:
- Oncology
- Nanomedicine
- Molecular Biology
Background:
- Gasdermin B (GSDMB) overexpression is prevalent in HER2 breast cancers, correlating with increased cell migration, therapeutic resistance, and poor prognosis.
- GSDMB's role in promoting aggressive tumor behavior necessitates novel therapeutic strategies targeting its intracellular functions.
Purpose of the Study:
- To develop and evaluate a targeted nanomedicine for intracellular delivery of an anti-GSDMB antibody in HER2 breast cancer.
- To investigate the efficacy of this nanomedicine in reducing GSDMB-driven tumor cell migration, enhancing anti-HER2 therapy response, and inhibiting tumor growth and metastasis.
Main Methods:
- Development of hyaluronic acid-based nanocapsules for targeted intracellular delivery of an anti-GSDMB antibody.
- In vitro and in vivo testing using HER2 breast cancer cell models and orthotopic xenografts.
- Assessment of GSDMB binding to sulfatides and its impact on cell death pathways.
Main Results:
- The anti-GSDMB antibody delivered via nanocapsules specifically reduced GSDMB-induced cell migration in vitro.
- Nanoparticle-delivered antibody enhanced sensitivity to trastuzumab and reduced tumor growth by increasing apoptosis in vivo.
- Therapy significantly diminished lung metastasis in MDA-MB-231-HER2 cells and was linked to increased GSDMB-sulfatide binding.
Conclusions:
- This study presents the first evidence of an effective antibody-based nanomedicine targeting an intracellular oncoprotein (GSDMB).
- Intracellular delivery of anti-GSDMB antibody successfully inhibited key protumor functions, including migration, metastasis, and therapy resistance.
- This nanomedicine represents a promising new targeted therapeutic strategy for aggressive HER2-positive breast cancers with poor outcomes.
More Related Videos
05:02Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells
Published on: February 4, 2021
07:13Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
Published on: March 26, 2014
Related Concept Videos
Aggression
Targeted Cancer Therapies
There are several types of targeted therapies against...
Intracellular Signaling Cascades
Reducing Line Loss
With a step-up transformer at the source, the voltage is increased, thereby reducing the current in the transmission lines since power loss in...
Secondary Motives: Affiliation Motivation and Aggression Motivation
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...